| A109 |
Rosopatamab Biosimilar(Anti-FOLH1 / PSMA Reference Antibody)
Featured
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency. |
.png)
|
| A110 |
Pelgifatamab Biosimilar(Anti-FOLH1 / PSMA Reference Antibody)
Featured
|
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research. |
.png)
|
| A111 |
Mirvetuximab Biosimilar(Anti-FOLR1 / FRA Reference Antibody)
Featured
|
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research. |
.png)
|
| DC66695 |
Cofrogliptin
Featured
|
Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) . |
|
| DC66696 |
(R)-2-Thioxothiazolidine-4-carboxylic acid-13C3
Featured
|
(R)-2-Thioxothiazolidine-4-carboxylic acid-13C3 is the 13C-labeled (R)-2-Thioxothiazolidine-4-carboxylic acid. Radioactive isotopes labeled compounds can be used in metabolic analysis, allowing the movement of individual atoms to be precisely tracked and quantified. |
|
| DC66697 |
2-Thioxothiazolidine-4-carboxylic Acid
Featured
|
|
|
| DC66698 |
STING agonist-12
Featured
|
STING agonist-12 (Compound 53) is a potent, orally active human STING activator with an EC50 of 185 nM. |
|
| A619 |
Sacituzumab govitecan
Featured
|
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity. |
|
| DC66700 |
(S,R)-LSN3318839
Featured
|
(S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R). |
|
| DC66701 |
(3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)pyrrolidin-3-ol
Featured
|
|
|
| A112 |
Farletuzumab Biosimilar(Anti-FOLR1 / FRA Reference Antibody)
Featured
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. |
.png)
|
| A114 |
Dompe patent anti-FOLR1 Biosimilar(Anti-FOLR1 / FRA Reference Antibody)
Featured
|
|
|
| A116 |
BMS-986012 Biosimilar（Anti-Fucosyl GM1 Reference Antibody）
Featured
|
|
|
| A130 |
Vantictumab Biosimilar（Anti-FZD Reference Antibody）
Featured
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma. |
.png)
|
| A131 |
U.Toronto patent anti-FZD7 Biosimilar（Anti-FZD7 Reference Antibody）
Featured
|
|
|
| DC60641 |
CD-005
Featured
|
CD-005 is a low-molecular-weight gelator that can be used to prepare gels for proteins and vaccines. CD-005 can physically entrap proteins, preventing their irreversible aggregation, and maintain protein function for at least 4 weeks even at temperatures up to 50°C. |
|
| DC66707 |
Casdatifan
Featured
|
Casdatifanum is a hypoxia-inducible factor (HIF) inhibitor. |
|
| DC66708 |
BMS-986408
Featured
|
BMS-986408 is a DGK inhibitor. |
|
| DC66709 |
BAY-2925976
Featured
|
BAY-2925976 is an ARα2C antagonist. |
|
| DC66710 |
AZD4144
Featured
|
AZD4144 is an NLRP3 inhibitor. |
|
| DC66711 |
CHF-6523
Featured
|
CHF-6523 is an inhaled PI3Kδ inhibitor. |
|
| DC66712 |
BAY-2413555
Featured
|
|
|
| DC66713 |
NVP-EVS459
Featured
|
|
|
| DC60642 |
Compound 33 (HYOU1 inhibitor)
Featured
|
Compound 33 (HYOU1 inhibitor) is a first-in-class inhibitor of hypoxia up-regulated protein 1 (HYOU1) with EC50 of 3.2 μM/2.6 μM/16.1 μM/3.0 μM in WT-MIP3/WT-RANTES/hTNFtg-MIP3/hTNFtg-RANTES, respectively. |
.png)
|
| DC60643 |
BRD-810
Featured
|
BRD-810 is a potent and selective MCL1 inhibitor with Kd of 0.3 nM (SPR) and IC50 of 0.4 nM (MCL1-Noxa HTRF), respectively. BRD-810 is a rapidly cleared inhibitor of MCL1 that has robust antitumor efficacy in hematological and solid tumor cancer models. |
|
| DC60644 |
ERAS-0015
Featured
|
ERAS-0015 is a pan-RAS modulator glue and demonstrates siganificantly more potent inhibition of cellular proliferation across KRAS mutant cell lines vs RMC-6236. |
|
| DC60645 |
CBPD-409
Featured
|
CBPD-409 is a highly potent, selective and orally bioavailable PROTAC degrader of CBP/p300. CBPD-409 induces robust CBP/p300 degradation with DC50 0.2-0.4 nM and displays strong antiproliferative effects with IC50 1.2-2.0 nM in the VCaP, LNCaP, and 22Rvl AR+ prostatcancer cell lines. |
|
| DC60646 |
GSDMD agonist DMB (C-185)
Featured
|
GSDMD agonist DMB is a direct and selective gasdermin D (GSDMD) agonist, activates GSDMD pore formation to trigger liposome leakage with EC50 of 0.7 uM, activates GSDMD pore formation and pyroptosis without cleaving GSDMD.
DMB directly binds to GSDMD by microscale thermophoresis (MST) with a dissociation constant (KD) of 1.1 uM.
DMB induces pyroptosis in immortalized and primary cells in a GSDMD-dependent and cleavage-independent manner.
DMB binds to GSDMD and induces cleavage-independent GSDMD oligomerization and pore formation. activated human GSDMD but not other human gasdermins, also activates mouse GSDMD in the liposome leakage assay, albeit with ∼5-fold reduced efficacy.
GSDMD agonist DMB modifies GSDMD at C191, which is conserved in GSDMD from different species but not in other gasdermin family members.
DMB induces tumor regression and enhances antitumor immunity that depends on GSDMD expression in the tumor. |
|
| DC66715 |
HSPC
Featured
|
HSPC is a natural product. Hydrogenated soya phosphatidylcholines can extend drug release in regard to drug loading and solubility for oral drug delivery of watersoluble drugs. |
.gif)
|
| DC66723 |
Isopropyl stearate
Featured
|
Isopropyl stearate (Stearic acid,isopropyl ester) is an ester product. |
|
